Comparison of Non-compartmental Analysis Estimation and Population Pharmacokinetic Predictions of Exposure Changes as a Function of Renal Impairment

Mariam Ahmed, Ph.D.

Mentor: Islam R. Younis, M.S, Ph.D.

Office of Clinical Pharmacology

Office of Translational Sciences

US Food and Drug Administration

Disclaimer

FDA

The opinions expressed in this presentation are those of the authors. No official FDA guidance should be taken or inferred from this presentation

Research Objective

FDA

To compare exposure changes as a function of renal impairment utilizing

1. Non-compartmental analysis estimation
2. Population pharmacokinetics predictions

Methods: Inclusion/Exclusion Criteria

FDA

Survey of NMEs (2000 and 2015) (N=373) → Dedicated Renal impairment Study (Full Study Design) (N=100) → Dedicated RIS and PopPK from Phase II/III (N=44)

↓

Reports available (N=28)

RFI is not significant covariate (N=10)

Combination drugs (N=1)

Total # of NMEs Included (N=17)

# Excluded Cases

Methods

- Renal impairment classification was based on C-G equation as follows:
  - Normal: CrCL ≥ 80 mL/min
  - Mild: CrCL ≥ 50-<80 mL/min
  - Moderate: CrCL ≥ 30-<50 mL/min
  - Severe: CrCL<30 mL/min
- Submitted PopPK models were used to predict observed AUC for each subject enrolled in RIS
  - 1000 simulation per subject
  - The non-parametric prediction interval for AUC GMR was calculated by computing the 5th and 95th percentiles of the model-based predicted GMR based on the 1000 simulations

Results: Description

FDA

	Normal Renal Function	Mild Renal Impairment	Moderate Renal Impairment	Severe Renal Impairment
RIS				
Median Number of Subjects Included	8	8	7	6
PopPK				
Median Number of Subjects Included	636	166	12	4

Results: Concordance

Number of Cases where AUC Geometric Mean Ratios (GMR) was not within the Same Fold		
Mild	**Moderate**	**Severe**
0/17 (0%)	4/16 (25%)	5/17 (29%)

Potential Factors for Differences

- Fraction excreted in urine.

- Inclusion of RIS data in PopPK model development

- Number of subjects with renal impairment in phase II/III trials

- Covariate model
  – Inclusion of correlated covariates

Results: Colinearity of Covariates was a Major Factor in Differences

Number of Cases where AUC Geometric Mean Ratios (GMR) was not within the Same Fold

	Mild	Moderate	Severe
Colinearity	0/7 (0%)	4/7 (57%)	4/7 (57%)
No colinearity	0/10 (0%)	0/9 (0%)	1/10 (10%)

Conclusions

- In general, there is a good concordance between PopPK and NCA results

- Inclusion of correlated covariates in model development increases the discordance between PopPK predictions and NCA analysis

Acknowledgments

FDA

- **Mentor: Islam R. Younis, Ph.D.**
- **Jeffry Florian , Ph.D.**
- **Rajnikanth Madabushi, Ph.D.**